Correction to: Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer's disease in individuals with subjective cognitive decline

Alzheimers Res Ther. 2021 Jan 15;13(1):25. doi: 10.1186/s13195-021-00770-2.

Julia Stockmann^{1

2}, Inge M W Verberk^{3

4}, Nina Timmesfeld⁵, Robin Denz⁵, Brian Budde^{1

2}, Julia Lange-Leifhelm^{1

2}, Philip Scheltens⁴, Wiesje M van der Flier⁴, Andreas Nabers^{1

2}, Charlotte E Teunissen³, Klaus Gerwert^{6

7}

¹ Competence Center for Biospectroscopy, Center for Protein Diagnostics (PRODI), Ruhr-University Bochum, Bochum, Germany.
² Department of Biophysics, Faculty of Biology and Biotechnology, Ruhr University Bochum, Bochum, Germany.
³ Department of Clinical Chemistry, Neurochemistry Laboratory, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.
⁴ Department of Neurology, Alzheimer Center Amsterdam, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.
⁵ Department of Medical Informatics, Biometry and Epidemiology, Ruhr University Bochum, Bochum, Germany.
⁶ Competence Center for Biospectroscopy, Center for Protein Diagnostics (PRODI), Ruhr-University Bochum, Bochum, Germany. klaus.gerwert@rub.de.
⁷ Department of Biophysics, Faculty of Biology and Biotechnology, Ruhr University Bochum, Bochum, Germany. klaus.gerwert@rub.de.

No abstract available

Publication types